Aplicações Clínicas da Ciclosporina Tópica em Oftalmologia

Revisão para Oftalmologistas

Autores

  • Fernando Faria-Correia Serviço de Oftalmologia, CUF Porto, Porto, Portugal; Oftalconde, Porto, Portugal; Serviço de Oftalmologia, Hospital de Braga, Braga, Portugal; Escola de Medicina da Universidade do Minho, Braga, Portugal; Rio de Janeiro Corneal Tomography and Biomechanics Study Group
  • Sara Ribeiro Serviço de Oftalmologia, CUF Porto, Porto, Portugal; Oftalconde, Porto, Portugal; Serviço de Oftalmologia, Hospital de Braga, Braga, Portugal; Escola de Medicina da Universidade do Minho, Braga, Portugal
  • Rui Silva Hospital de Braga, Braga, Portugal
  • Álvaro Silva Hospital de Braga, Braga, Portugal
  • Carlos Cruz Hospital de Braga, Braga, Portugal
  • Christophe Pinto Hospital de Braga, Braga, Portugal
  • Marina Delgado João Hospital de Braga, Braga, Portugal
  • Jorge Vasco Costa Hospital de Braga, Braga, Portugal
  • Bernardo T. Lopes Rio de Janeiro Corneal Tomography and Biomechanics Study Group; VisareRio, Rio de Janeiro; Instituto de Olhos Renato Ambrósio, Rio de Janeiro, Brasil; Universidade Federal de São Paulo (UNIFESP), São Paulo, Brasil; School of Engineering, University of Liverpool, Liverpool, Reuni Unido
  • Joana Mello Amaral VisareRio, Rio de Janeiro, Brazil; Instituto de Olhos Renato Ambrósio, Rio de Janeiro, Brazil
  • Faride W. Tanos VisareRio, Rio de Janeiro, Brazil; Instituto de Olhos Renato Ambrósio, Rio de Janeiro, Brazil
  • Marcella Q. Salomão VisareRio, Rio de Janeiro, Brasil; Instituto de Olhos Renato Ambrósio, Rio de Janeiro, Brasil; Universidade Federal de São Paulo (UNIFESP), São Paulo, Brasil
  • Sandra Rodrigues-Barros Rio de Janeiro Corneal Tomography and Biomechanics Study Group; Serviço de Oftalmologia, Hospital Garcia da Orta, Almada, Lisboa, Portugal; Serviço de Oftalmologia, CUF Almada e CUF Cascais, Portugal
  • Pedro Baptista Rio de Janeiro Corneal Tomography and Biomechanics Study Group; Serviço de Oftalmologia, Centro Hospitalar Universitário do Porto, Porto, Portugal
  • Nuno Franqueira Serviço de Oftalmologia, Hospital de Braga, Braga, Portugal; VisareRio, Rio de Janeiro, Brasil
  • José Carlos Mendes Serviço de Oftalmologia, Hospital de Braga, Braga, Portugal
  • Tiago Monteiro Serviço de Oftalmologia, CUF Porto, Porto, Portugal; Oftalconde, Porto, Portugal; Serviço de Oftalmologia, Hospital de Braga, Braga, Portugal; Escola de Medicina da Universidade do Minho, Braga, Portugal
  • Fernando Vaz Serviço de Oftalmologia, CUF Porto, Porto, Portugal; Serviço de Oftalmologia, Hospital de Braga, Braga, Portugal; Escola de Medicina da Universidade do Minho, Braga, Portugal
  • Renato Ambrósio, Jr. Rio de Janeiro Corneal Tomography and Biomechanics Study Group; VisareRio, Rio de Janeiro, Brasil; Instituto de Olhos Renato Ambrósio, Rio de Janeiro, Brasil; Universidade Federal de São Paulo (UNIFESP), São Paulo, Brasil; Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rio de Janeiro, Brasil

Palavras-chave:

Administração Oftálmica, Ciclosporina/uso terapêutico, Olho, Síndro-mes do Olho Seco, Soluções Oftálmicas

Resumo

A ciclosporina A (CsA) é um agente imunomodulador que apresenta uma ação inibtória selectiva sobre os linfócitos células T. O CsA tópico com várias formulações tem sido usado na Oftalmologia. Este artigo tem como objetivo apresentar uma revisão da literatura científica publicada revisada por pares e ilustrar algumas aplicações da CsA na áreas das doenças da superfície ocular.

Downloads

Não há dados estatísticos.

Referências

Borel JF, Feurer C, Magnee C, Stahelin H. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology. 1977;32:1017-25.

Bushley KE, Raja R, Jaiswal P, Cumbie JS, Nonogaki M, Boyd AE, et al. The genome of tolypocladium inflatum: evolution, organization, and expression of the cyclosporin biosynthetic gene cluster. PLoS Genet. 2013;9:e1003496.

Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev. 2006:CD005161.

Matsuda S, Koyasu S. Mechanisms of action of cyclos-porine. Immunopharmacology. 2000;47:119-25.

Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhi-bited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A. 1992;89:3686-90.

Halloran PF, Kung L, Noujaim J. Calcineurin and the biological effect of cyclosporine and tacrolimus. Transplant Proc. 1998;30:2167-70.

Waldmeier PC, Zimmermann K, Qian T, Tintelnot--Blomley M, Lemasters JJ. Cyclophilin D as a drug tar-get. Curr Med Chem. 2003;10:1485-506.

Du S, Hiramatsu N, Hayakawa K, Kasai A, Okamu-ra M, Huang T, et al. Suppression of NF-kappaB by cyclosporin a and tacrolimus (FK506) via induction of the C/EBP family: implication for unfolded protein response. J Immunol. 2009;182:7201-11.

Ames P, Galor A. Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence. Clin Investig. 2015;5:267-85.

Matsuda S, Moriguchi T, Koyasu S, Nishida E. T lym-phocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SA-PK/JNK signaling pathways sensitive to cyclosporin A. J Biol Chem. 1998;273:12378-82.

Li Y, Johnson N, Capano M, Edwards M, Crompton M. Cyclophilin-D promotes the mitochondrial permeability transition but has opposite effects on apoptosis and necrosis. Biochem J. 2004;383:101-9.

Gao J, Sana R, Calder V, Calonge M, Lee W, Wheeler LA, et al. Mitochondrial permeability transition pore in inflammatory apoptosis of human conjunctival epi-thelial cells and T cells: effect of cyclosporin A. Invest Ophthalmol Vis Sci. 2013;54:4717-33.

Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004;305:626-9.

Wang HG, Pathan N, Ethell IM, Krajewski S, Yama-guchi Y, Shibasaki F, et al. Ca2+-induced apopto-sis through calcineurin dephosphorylation of BAD. Science. 1999;284:339-43.

Lallemand F, Furrer P, Felt-Baeyens O, Gex-Fabry M, Dumont JM, Besseghir K, et al. A novel water-soluble cyclosporine A prodrug: ocular tolerance and in vivo kinetics. Int J Pharm. 2005;295:7-14.

Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology. 2007;114:76-9.

Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15:276-83.

Agarwal P, Rupenthal ID. Modern approaches to the ocular delivery of cyclosporine A. Drug Discov Today. 2016;21:977-88.

Boboridis KG, Konstas AGP. Evaluating the novel application of cyclosporine 0.1% in ocular surface di-sease. Expert Opin Pharmacother. 2018;19:1027-39.

Pisella PJ, Labetoulle M, Doan S, Cochener-Lamard B, Amrane M, Ismail D, et al. Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program. Clin Ophthalmol. 2018;12:289-99.

Vaishya RD, Khurana V, Patel S, Mitra AK. Controlled ocular drug delivery with nanomicelles. Wiley Inter-discip Rev Nanomed Nanobiotechnol. 2014;6:422-37.

Cholkar K, Gilger BC, Mitra AK. Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery. Transl Vis Sci Technol. 2015;4:1.

Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, et al. A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. Clin Ophthalmol. 2018;12:1921-9.

Karpecki PM, Weiss SL, Kramer WG, O’Connor P, Evans D, Johnston J, et al. A phase 1, open-label, sin-gle-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers. Clin Ophthalmol. 2019;13:591-6.

Mandal A, Gote V, Pal D, Ogundele A, Mitra AK. Ocu-lar Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa(R)) for Dry Eye Disease. Pharm Res. 2019;36:36.

Weiss SL, Kramer WG. Ocular Distribution of Cyclosporine Following Topical Administration of OTX-101 in New Zealand White Rabbits. J Ocul Pharmacol Ther. 2019;35:395-402.27.Gumus K, Mirza GE, Cavanagh HD, Karakucuk S. Topical cyclosporine A as a steroid-sparing agent in steroid-dependent idiopathic ocular myositis with scleritis: a case report and review of the literature. Eye Contact Lens. 2009;35:275-8.

de Oliveira RC, Wilson SE. Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease. Clin Ophthalmol. 2019;13:1115-22.

Sall K, Stevenson OD, Mundorf TK, Reis BL. Two mul-ticenter, randomized studies of the efficacy and safe-ty of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107:631-9.

Periman LM, Perez VL, Saban DR, Lin MC, Neri P. The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options. J Ocul Pharmacol Ther. 2020;36:137-46.

Periman LM, Mah FS, Karpecki PM. A review of the mechanism of action of cyclosporine A: the role of cyclosporine A in dry eye disease and recent formulation developments. Clin Ophthalmol. 2020;14:4187-200.

Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438-510.

Szalai E, Berta A, Szekanecz Z, Szucs G, Modis L, Jr. Evaluation of tear osmolarity in non-Sjogren and Sjogren syndrome dry eye patients with the TearLab sys-tem. Cornea. 2012;31:867-71.

Versura P, Campos EC. TearLab(R) Osmolarity Sys-tem for diagnosing dry eye. Expert Rev Mol Diagn.2013;13:119-29.

Potvin R, Makari S, Rapuano CJ. Tear film osmolarity and dry eye disease: a review of the literature. Clin Ophthalmol. 2015;9:2039-47.

Bunya VY, Pistilli M, Ying GS. Progressively Increased Variation in Tear Osmolarity Mirrors Dry Eye Severity-Reply. JAMA Ophthalmol. 2015;133:1482.

Iwata M, Soya K, Sawa M, Sakimoto T, Hwang DG. CD40 expression in normal human cornea and regulation of CD40 in cultured human corneal epithelial and stromal cells. Invest Ophthalmol Vis Sci. 2002;43:348-57.

Hessen M, Akpek EK. Dry eye: an inflammatory ocu-lar disease. J Ophthalmic Vis Res. 2014;9:240-50.39.

Messmer EM, von Lindenfels V, Garbe A, Kampik A. Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay. Ophthalmology. 2016;123:2300-8.

Park JY, Kim BG, Kim JS, Hwang JH. Matrix Metalloproteinase 9 Point-of-Care Immunoassay Result Predicts Response to Topical Cyclosporine Treatment in Dry Eye Disease. Transl Vis Sci Technol. 2018;7:31.

Arman A, Demirseren DD, Takmaz T. Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline. Int J Ophthalmol. 2015;8:544-9.

Machalinska A, Zakrzewska A, Markowska A, Sa-franow K, Wiszniewska B, Parafiniuk M, et al. Morphological and Functional Evaluation of Meibomian Gland Dysfunction in Rosacea Patients. Curr Eye Res. 2016;41:1029-34.

Bilgin B, Karadag AS. Effects of combined oral doxycycline and topical cyclosporine treatment on ocular signs, symptoms, and tear film parameters in rosacea patients. Arq Bras Oftalmol. 2018;81:466-70.

Trattler WB, Majmudar PA, Donnenfeld ED, McDo-nald MB, Stonecipher KG, Goldberg DF. The Prospective Health Assessment of Cataract Patients’ Ocular Surface (PHACO) study: the effect of dry eye. Clin Ophthalmol. 2017;11:1423-30.

Schultz CL, Kunert KS. Interleukin-6 levels in tears of contact lens wearers. J Interferon Cytokine Res. 2000;20:309-10.

Cakmak SS, Unlu MK, Karaca C, Nergiz Y, Ipek S. Effects of soft contact lenses on conjunctival surface. Eye Contact Lens. 2003;29:230-3.

Hom MM. Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients. Eye Contact Lens. 2006;32:109-11.48.Foster CS, Rice BA, Dutt JE. Immunopatholo-gy of atopic keratoconjunctivitis. Ophthalmology. 1991;98:1190-6.

Metz DP, Hingorani M, Calder VL, Buckley RJ, Lightman SL. T-cell cytokines in chronic allergic eye disease. J Allergy Clin Immunol. 1997;100:817-24.

Oray M, Toker E. Tear cytokine levels in vernal keratoconjunctivitis: the effect of topical 0.05% cyclosporine a therapy. Cornea. 2013;32:1149-54.51.

Westland T, Patryn EK, Nieuwendaal CP, van der Meulen IJE, Mourits MP, Lapid-Gortzak R. Vernal shield ulcers treated with frequently installed topical cyclosporine 0.05% eyedrops. Int Ophthalmol. 2018;38:363-8.

Keklikci U, Dursun B, Cingu AK. Topical cyclosporine a 0.05% eyedrops in the treatment of vernal keratoconjunctivitis - randomized placebo-controlled trial. Adv Clin Exp Med. 2014;23:455-61.

Yucel OE, Ulus ND. Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis. Singapore Med J. 2016;57:507-10.

Chatterjee A, Bandyopadhyay S, Kumar Bandyopa-dhyay S. Efficacy, safety and steroid-sparing effect of topical cyclosporine A 0.05% for vernal keratoconjunctivitis in indian children. J Ophthalmic Vis Res. 2019;14:412-8.

Vichyanond P, Kosrirukvongs P. Use of cyclosporine A and tacrolimus in treatment of vernal keratocon-junctivitis. Curr Allergy Asthma Rep. 2013;13:308-14.56.Kilic A, Gurler B. Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis. Can J Ophthalmol. 2006;41:693-8.

Wilson SE. Laser in situ keratomileusis-induced (pre-sumed) neurotrophic epitheliopathy. Ophthalmology. 2001;108:1082-7.

Wilson SE, Ambrosio R. Laser in situ keratomileusis-induced neurotrophic epitheliopathy. Am J Ophthal-mol. 2001;132:405-6.

Salomao MQ, Ambrosio R, Jr., Wilson SE. Dry eye as-sociated with laser in situ keratomileusis: Mechanical microkeratome versus femtosecond laser. J Cataract Refract Surg. 2009;35:1756-60.

Reinstein DZ, Archer TJ, Gobbe M, Bartoli E. Corneal sensitivity after small-incision lenticule extraction and laser in situ keratomileusis. J Cataract Refract Surg. 2015;41:1580-7.

Kanellopoulos AJ. Incidence and management of symptomatic dry eye related to LASIK for myopia, with topical cyclosporine A. Clin Ophthalmol. 2019;13:545-52.

Dietrich-Ntoukas T, Cursiefen C, Westekemper H, Eberwein P, Reinhard T, Bertz H, et al. Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD. Cornea. 2012;31:299-310.

Westekemper H, Scholz SL, Thomasen H, Halfwassen C, Steuhl KP. Ocular graft versus host disease : Corneal complications . Ophthalmologe. 2017;114:697-702.

Malta JB, Soong HK, Shtein RM, Musch DC, Rhoades W, Sugar A, et al. Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%. Cornea. 2010;29:1392-6.

Lee HY, Fook-Chong S, Koh HY, Thirumoorthy T, Pang SM. Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center. J Am Acad Dermatol. 2017;76:106-13.

Prabhasawat P, Tesavibul N, Karnchanachetanee C, Kasemson S. Efficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eye. J Ocul Pharmacol Ther. 2013;29:372-7

Branisteanu DC, Stoleriu G, Branisteanu DE, BodaD, Branisteanu CI, Maranduca MA, et al. Ocular cicatricial pemphigoid (Review). Exp Ther Med. 2020;20:3379-82.68.

Valerio GS, Lin CC. Ocular manifestations of her-pes simplex virus. Curr Opin Ophthalmol. 2019;30:525-31.

Lobo AM, Agelidis AM, Shukla D. Pathogenesis of herpes simplex keratitis: The host cell response and ocular surface sequelae to infection and inflammation. Ocul Surf. 2019;17:40-9.

Khan BF, Pavan-Langston D. Clinical manifestations and treatment modalities in herpes simplex virus of the ocular anterior segment. Int Ophthalmol Clin. 2004;44:103-33.71.

Peyman A, Nayebzadeh M, Peyman M, Afshari NA, Pourazizi M. Topical cyclosporine-A versus prednisolone for herpetic stromal keratitis: a randomized controlled trial. Acta Ophthalmol. 2019;97:e194-e8.

Rao SN. Treatment of herpes simplex virus stromal keratitis unresponsive to topical prednisolone 1% with topical cyclosporine 0.05%. Am J Ophthalmol. 2006;141:771-2.

Zghal I, Fekih O, Zgolli HM, Chargui S, Malek I, Nacef L. Cyclosporin A eye drop and subepithelial adenoviral keratoconjunctivitis infiltrates. Tunis Med. 2019;97:639-43.74.

Ozulken K, Koc M, Ayar O, Hasiripi H. Topical cyclosporine A administration after pterygium surgery. Eur J Ophthalmol. 2012;22 Suppl 7:S5-10.

Zhang Q, Bao N, Liang K, Tao L. Adjuvant Use of Cyclosporine A in the Treatment of Primary Pterygium: A Systematic Review and Meta-Analysis. Cornea. 2018;37:1000-7.

Han JW, Yoon JS, Jang SY. Short-term effects of topical cyclosporine A 0.05% (Restasis) in long-standing prosthetic eye wearers: a pilot study. Eye. 2014;28:1212-7.

de Paiva CS, Pflugfelder SC, Ng SM, Akpek EK. Topical cyclosporine A therapy for dry eye syndrome. Co-chrane Database Syst Rev. 2019;9:CD010051.

Downloads

Publicado

2021-03-31

Como Citar

Faria Correia, F., Ribeiro, S., Silva, R., Silva, Álvaro, Cruz, C., Pinto, C., Delgado João, M., Vasco Costa, J., T. Lopes, B., Mello Amaral, J., W. Tanos, F., Q. Salomão, M., Rodrigues-Barros, S., Baptista, P., Franqueira, N., Mendes, J., Monteiro, T., Vaz, F., & Ambrósio, Jr., R. (2021). Aplicações Clínicas da Ciclosporina Tópica em Oftalmologia: Revisão para Oftalmologistas. Revista Sociedade Portuguesa De Oftalmologia, 45(1), 37–44. Obtido de https://revistas.rcaap.pt/index.php/oftalmologia/article/view/23711

Edição

Secção

Artigos de Revisão